Nakahama H, Nakanishi T, Uyama O, Sugita M, Miyazaki M, Yokokawa T, Okamura K, Tanaka Y, Shirai D
Fifth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Ren Fail. 1993;15(2):189-93. doi: 10.3109/08860229309046151.
Lp(a) is an LDL-like lipoprotein carrying the apoprotein(a) glycoprotein and has recently been recognized to be an independent risk factor for coronary heart disease. We studied plasma Lp(a) levels in 40 patients undergoing maintenance hemodialysis (24 male, 16 female; aged 16-83 years). Fasting plasma Lp(a) levels were measured by an enzyme-linked immunosorbent assay. The median value of plasma Lp(a) concentrations in hemodialysis patients was significantly higher than that of the normal volunteers (26.0 +/- 2.7 vs. 10.8 +/- 3.7 mg/dL, p < .05). Lp(a) levels did not correlate with age, duration of hemodialysis, total cholesterol, triglyceride, HDL cholesterol, or LDL cholesterol. The 11 patients whose plasma Lp(a) concentrations exceeded 20 mg/dL received niceritrol, a prodrug of nicotinic acid, at a dosage of 500 mg t.i.d. for 4 weeks. The plasma Lp(a) levels were significantly lower after 4 weeks of treatment (38.3 +/- 4.2 vs. 31.5 +/- 3.2 mg/dL, p < .01).
脂蛋白(a)是一种携带载脂蛋白(a)糖蛋白的低密度脂蛋白样脂蛋白，最近被认为是冠心病的独立危险因素。我们研究了40例维持性血液透析患者（24例男性，16例女性；年龄16 - 83岁）的血浆脂蛋白(a)水平。采用酶联免疫吸附测定法测量空腹血浆脂蛋白(a)水平。血液透析患者血浆脂蛋白(a)浓度的中位数显著高于正常志愿者（26.0±2.7对10.8±3.7mg/dL，p<0.05）。脂蛋白(a)水平与年龄、血液透析时间、总胆固醇、甘油三酯、高密度脂蛋白胆固醇或低密度脂蛋白胆固醇均无相关性。11例血浆脂蛋白(a)浓度超过20mg/dL的患者接受了烟酸前体药物尼可占替诺，剂量为500mg，每日三次，共4周。治疗4周后血浆脂蛋白(a)水平显著降低（38.3±4.2对31.5±3.2mg/dL，p<0.01）。
